HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

Cancer

Volumn 120, Issue 3, 2014, Pages 373-380

  Strati, Paolo ^a   Kantarjian, Hagop ^a   Thomas, Deborah ^a   O'Brien, Susan ^a   Konoplev, Sergej ^a   Jorgensen, Jeffrey L ^a   Luthra, Raja ^a   Abruzzo, Lynne ^a   Jabbour, Elias ^a   Quintas Cardama, Alfonso ^a   Borthakur, Gautam ^a   Faderl, Stefan ^a   Ravandi, Farhad ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

blast phase; chronic myeloid leukemia; HCVAD; lymphoid variant; tyrosine kinase inhibitors

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; IMATINIB; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CEREBROVASCULAR ACCIDENT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DISEASE COURSE; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; LYMPHATIC LEUKEMIA; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; OUTCOMES RESEARCH; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

BLAST PHASE; CHRONIC MYELOID LEUKEMIA; HCVAD; LYMPHOID VARIANT; TYROSINE KINASE INHIBITORS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; BLAST CRISIS; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; METHOTREXATE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; THIAZOLES; VINCRISTINE;

EID: 84892944529     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28433     Document Type: Article

References (33)

1. Karanas A, Silver RT,. Characteristics of the terminal phase of chronic granulocytic leukemia. Blood. 1968; 32: 445-459.
2. Silver RT,. The blast phase of chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009; 22: 387-394.
3. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408-2417.
4. Krulik M, Smadja N, de Gramont A, Gonzalez-Canali G, Audebert AA, Dray C, Brissaud P, Debray J,. Sequential karyotype study on Ph-positive chronic myelocytic leukemia. Significance of additional chromosomal abnormalities during disease evolution. Cancer. 1987; 60: 974-979.
5. Hehlmann R,. How I treat CML blast crisis. Blood. 2012; 120: 737-747.
6. Palandri F, Castagnetti F, Testoni N, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica. 2008; 93: 1792-1796.
7. Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia. 2008; 22: 2176-2183.
8. Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2010; 115: 1880-1885.
9. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002; 99: 319-325.
10. Fruehauf S, Topaly J, Buss EC, et al. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer. 2007; 109: 1543-1549.
11. Oki Y, Kantarjian HM, Gharibyan V, et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 2007; 109: 899-906.
12. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma. 2007; 48: 283-289.
13. Fang B, Li N, Song Y, Han Q, Zhao RC,. Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib. Ann Hematol. 2010; 89: 1099-1105.
14. Verma D, Kantarjian HM, Jones D, et al. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood. 2009; 114: 2232-2235.
15. Kawano N, Okuda S, Yoshida S, et al. Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation. Int J Hematol. 2011; 94: 561-566.
16. Weir EG, Cowan K, LeBeau P, Borowitz MJ,. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia. 1999; 13: 558-567.
17. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000; 18: 547-561.
18. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004; 103: 4396-4407.
19. Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010; 116: 2070-2077.
20. Karbasian Esfahani M, Morris EL, Dutcher JP, Wiernik PH,. Blastic phase of chronic myelogenous leukemia. Curr Treat Options Oncol. 2006; 7: 189-199.
21. Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011; 118: 6760-6768.
22. Mitelman F, Levan G, Nilsson PG, Brandt L,. Nonrandom karyotypic evolution in chronic myeloid leukemia. Int J Cancer. 1976; 18: 24-30.
23. Alimena G, De Cuia MR, Diverio D, Gastaldi R, Nanni M,. The karyotype of blastic crisis. Cancer Genet Cytogenet. 1987; 26: 39-50.
24. Johansson B, Fioretos T, Mitelman F,. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002; 107: 76-94.
25. Marmont AM, Damasio EE,. The treatment of terminal metamorphosis of chronic granulocytic leukaemia with corticosteroids and vincristine. Acta Haematol. 1973; 50: 1-8.
26. Marks SM, Baltimore D, McCaffrey R,. Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia. N Engl J Med. 1978; 298: 812-814.
27. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011; 12: 841-851.
28. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012; 119: 1123-1129.
29. Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004; 36: 453-461.
30. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome positive leukemias. N Engl J Med. 2006; 354: 2531-2541.
31. Ilaria RL Jr,. Pathobiology of lymphoid and myeloid blast crisis and management issues. Hematology Am Soc Hematol Educ Program. 2005;1: 188-194.
32. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994-1004.
33. Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 2005; 106: 2128-2137.